JP2007535471A5 - - Google Patents

Download PDF

Info

Publication number
JP2007535471A5
JP2007535471A5 JP2006509122A JP2006509122A JP2007535471A5 JP 2007535471 A5 JP2007535471 A5 JP 2007535471A5 JP 2006509122 A JP2006509122 A JP 2006509122A JP 2006509122 A JP2006509122 A JP 2006509122A JP 2007535471 A5 JP2007535471 A5 JP 2007535471A5
Authority
JP
Japan
Prior art keywords
antibody
binds
library
cll
composition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2006509122A
Other languages
English (en)
Japanese (ja)
Other versions
JP2007535471A (ja
Filing date
Publication date
Priority claimed from US10/379,151 external-priority patent/US7435412B2/en
Priority claimed from US10/736,188 external-priority patent/US20040198661A1/en
Application filed filed Critical
Publication of JP2007535471A publication Critical patent/JP2007535471A/ja
Publication of JP2007535471A5 publication Critical patent/JP2007535471A5/ja
Pending legal-status Critical Current

Links

JP2006509122A 2003-03-04 2004-03-04 慢性リンパ性白血病細胞由来のポリペプチド及び抗体並びにそれらの関連する適用 Pending JP2007535471A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US10/379,151 US7435412B2 (en) 2000-12-08 2003-03-04 Chronic lymphocytic leukemia cell line
US10/379,151 2003-03-04
US10/736,188 US20040198661A1 (en) 2000-12-08 2003-12-15 Polypeptides and antibodies derived from chronic lymphocytic leukemia cells and uses thereof
US10/736,188 2003-12-15
PCT/US2004/006577 WO2004078938A2 (en) 2003-03-04 2004-03-04 Polypeptides and antibodies derived from chronic lymphocytic leukemia cells and uses thereof

Publications (2)

Publication Number Publication Date
JP2007535471A JP2007535471A (ja) 2007-12-06
JP2007535471A5 true JP2007535471A5 (cg-RX-API-DMAC7.html) 2008-01-24

Family

ID=32965320

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2006509122A Pending JP2007535471A (ja) 2003-03-04 2004-03-04 慢性リンパ性白血病細胞由来のポリペプチド及び抗体並びにそれらの関連する適用

Country Status (6)

Country Link
US (1) US20040198661A1 (cg-RX-API-DMAC7.html)
EP (1) EP1606388A4 (cg-RX-API-DMAC7.html)
JP (1) JP2007535471A (cg-RX-API-DMAC7.html)
KR (1) KR20050108381A (cg-RX-API-DMAC7.html)
CA (1) CA2517968A1 (cg-RX-API-DMAC7.html)
WO (1) WO2004078938A2 (cg-RX-API-DMAC7.html)

Families Citing this family (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2002246632B2 (en) * 2000-12-08 2007-04-05 Alexion Pharmaceuticals, Inc. Chronic lymphocytic leukemia cell line and its use for producing an antibody
US7408041B2 (en) * 2000-12-08 2008-08-05 Alexion Pharmaceuticals, Inc. Polypeptides and antibodies derived from chronic lymphocytic leukemia cells and uses thereof
US20060057651A1 (en) * 2000-12-08 2006-03-16 Bowdish Katherine S Polypeptides and antibodies derived from chronic lymphocytic leukemia cells and uses thereof
US9249229B2 (en) * 2000-12-08 2016-02-02 Alexion Pharmaceuticals, Inc. Polypeptides and antibodies derived from chronic lymphocytic leukemia cells and uses thereof
JP4381140B2 (ja) * 2001-10-12 2009-12-09 シェーリング コーポレイション 免疫応答を調節するための二重特異性抗体の使用
AU2012211347B9 (en) * 2004-07-20 2015-06-18 Alexion Pharmaceuticals, Inc. Polypeptides and antibodies derived from chronic lymphocytic leukemia cells and uses thereof
EP2463305B1 (en) * 2006-01-12 2016-05-11 Alexion Pharmaceuticals, Inc. Antibodies to OX-2/CD200 and uses thereof
WO2008089022A2 (en) * 2007-01-11 2008-07-24 Boehringer Ingelheim International Gmbh Cd200 and its receptor, cd200r, modulate bone mass via the differentiation of osteoclasts
US8252286B2 (en) 2007-05-21 2012-08-28 Alderbio Holdings Llc Antagonists of IL-6 to prevent or treat thrombosis
DK2164514T3 (en) 2007-05-21 2017-02-27 Alderbio Holdings Llc Antibodies to IL-6 and its use
US8404235B2 (en) 2007-05-21 2013-03-26 Alderbio Holdings Llc Antagonists of IL-6 to raise albumin and/or lower CRP
US8178101B2 (en) 2007-05-21 2012-05-15 Alderbio Holdings Inc. Use of anti-IL-6 antibodies having specific binding properties to treat cachexia
US9701747B2 (en) 2007-05-21 2017-07-11 Alderbio Holdings Llc Method of improving patient survivability and quality of life by anti-IL-6 antibody administration
US8062864B2 (en) 2007-05-21 2011-11-22 Alderbio Holdings Llc Nucleic acids encoding antibodies to IL-6, and recombinant production of anti-IL-6 antibodies
US7906117B2 (en) 2007-05-21 2011-03-15 Alderbio Holdings Llc Antagonists of IL-6 to prevent or treat cachexia, weakness, fatigue, and/or fever
CA2694121C (en) * 2007-07-25 2016-06-07 Alexion Pharmaceuticals, Inc. Methods and compositions for treating autoimmune disease
US8323649B2 (en) 2008-11-25 2012-12-04 Alderbio Holdings Llc Antibodies to IL-6 and use thereof
US8992920B2 (en) 2008-11-25 2015-03-31 Alderbio Holdings Llc Anti-IL-6 antibodies for the treatment of arthritis
US8420089B2 (en) 2008-11-25 2013-04-16 Alderbio Holdings Llc Antagonists of IL-6 to raise albumin and/or lower CRP
US9212223B2 (en) 2008-11-25 2015-12-15 Alderbio Holdings Llc Antagonists of IL-6 to prevent or treat thrombosis
KR20110091780A (ko) * 2008-11-25 2011-08-12 앨더 바이오파마슈티컬즈, 인코포레이티드 악액질, 쇠약, 피로 및/또는 발열을 예방하거나 치료하는 il­6의 길항제
US9452227B2 (en) 2008-11-25 2016-09-27 Alderbio Holdings Llc Methods of treating or diagnosing conditions associated with elevated IL-6 using anti-IL-6 antibodies or fragments
US8337847B2 (en) 2008-11-25 2012-12-25 Alderbio Holdings Llc Methods of treating anemia using anti-IL-6 antibodies
MX356367B (es) 2008-12-09 2018-05-25 Genentech Inc Anticuerpos anti-pd-l1 y su uso para mejorar la funcion de celulas t.
EP2477658A2 (en) * 2009-09-16 2012-07-25 Duke University Hiv-1 antibodies
US9775921B2 (en) 2009-11-24 2017-10-03 Alderbio Holdings Llc Subcutaneously administrable composition containing anti-IL-6 antibody
EP2504032A4 (en) 2009-11-24 2013-06-19 Alderbio Holdings Llc IL-6 ANTAGONISTS FOR PREVENTING OR TREATING THROMBOSIS
JP6012473B2 (ja) 2010-01-11 2016-10-25 アレクシオン ファーマシューティカルズ, インコーポレイテッド 抗cd200抗体を用いたヒトの処置における免疫調節効果のバイオマーカー
NZ601580A (en) 2010-02-11 2014-11-28 Alexion Pharma Inc Therapeutic methods using anti-cd200 antibodies
US8992908B2 (en) 2010-11-23 2015-03-31 Alderbio Holdings Llc Anti-IL-6 antibodies for the treatment of oral mucositis
TW201244737A (en) 2011-02-03 2012-11-16 Alexion Pharma Inc Use of an anti-CD200 antibody for prolonging the survival of allografts
US11492383B2 (en) 2011-06-24 2022-11-08 Stephen D. Gillies Light chain immunoglobulin fusion proteins and methods of use thereof
KR102379464B1 (ko) 2016-06-20 2022-03-29 키맵 리미티드 항-pd-l1 항체
WO2019067499A1 (en) 2017-09-27 2019-04-04 Alexion Pharmaceuticals, Inc. BIOMARKER SIGNATURE FOR PREDICTING A TUMOR RESPONSE TO ANTI-CD200 THERAPY
US12139533B2 (en) 2017-12-20 2024-11-12 Alexion Pharmaceuticals, Inc. Liquid formulations of anti-CD200 antibodies
US11802154B2 (en) 2017-12-20 2023-10-31 Alexion Pharmaceuticals, Inc. Humanized anti-CD200 antibodies and uses thereof

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3940475A (en) * 1970-06-11 1976-02-24 Biological Developments, Inc. Radioimmune method of assaying quantitatively for a hapten
US4289747A (en) * 1978-12-26 1981-09-15 E-Y Laboratories, Inc. Immunological determination using lectin
US4376110A (en) * 1980-08-04 1983-03-08 Hybritech, Incorporated Immunometric assays using monoclonal antibodies
US5225539A (en) * 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
US5223409A (en) * 1988-09-02 1993-06-29 Protein Engineering Corp. Directed evolution of novel binding proteins
US5427908A (en) * 1990-05-01 1995-06-27 Affymax Technologies N.V. Recombinant library screening methods
DE69129154T2 (de) * 1990-12-03 1998-08-20 Genentech, Inc., South San Francisco, Calif. Verfahren zur anreicherung von proteinvarianten mit geänderten bindungseigenschaften
US5780279A (en) * 1990-12-03 1998-07-14 Genentech, Inc. Method of selection of proteolytic cleavage sites by directed evolution and phagemid display
DE69226871T3 (de) * 1991-06-27 2009-09-24 Bristol-Myers Squibb Co. CTL4A-Rezeptor, ihn enthaltenden Fusionsproteine und deren Verwendung
US5508717A (en) * 1992-07-28 1996-04-16 Sony Corporation Computer pointing device with dynamic sensitivity
ATE219376T1 (de) * 1996-03-20 2002-07-15 Bristol Myers Squibb Co Verfahren zur inhibierung der immunreaktion durch blockierung der gp39/cd40 und ctla4/cd28/b7 routen und zusammensetzung zu deren verwendung
US6011138A (en) * 1997-02-20 2000-01-04 Idec Pharmaceuticals Corporation Gamma-1 anti-human CD23 monoclonal antibodies
PT1032662E (pt) * 1997-11-07 2006-07-31 Trillium Therapeutics Inc Metodos e composicoes para imunomodulacao.
US6955811B2 (en) * 1997-11-07 2005-10-18 Trillium Therapeutics Inc. Methods of inhibiting immune response suppression by administering antibodies to OX-2
US7223729B2 (en) * 1997-11-07 2007-05-29 Trillium Therapeutics Inc. Methods of treating allergy by administering a CD200 protein
US20020192215A1 (en) * 1999-04-13 2002-12-19 Schering Corporation, A New Jersey Corporation Novel uses of mammalian OX2 protein and related reagents
CA2403393A1 (en) * 2000-03-17 2001-09-20 Reginald M. Gorczynski Methods and compositions for immunoregulation
US7306801B2 (en) * 2000-05-15 2007-12-11 Health Research, Inc. Methods of therapy for cancers characterized by overexpression of the HER2 receptor protein
CA2417874C (en) * 2000-08-03 2012-10-02 Transplantation Technologies Inc. Use of ox-2 inhibitors for the treatment of cancer
US20030017491A1 (en) * 2000-09-14 2003-01-23 Zuo-Rong Shi Chromogenic in situ hybridization methods, kits, and compositions
AU2002223338B2 (en) * 2000-11-22 2007-06-07 Trillium Therapeutics Inc. Truncated CD200
AU2002246632B2 (en) * 2000-12-08 2007-04-05 Alexion Pharmaceuticals, Inc. Chronic lymphocytic leukemia cell line and its use for producing an antibody
US7408041B2 (en) * 2000-12-08 2008-08-05 Alexion Pharmaceuticals, Inc. Polypeptides and antibodies derived from chronic lymphocytic leukemia cells and uses thereof
US6953417B2 (en) * 2003-11-17 2005-10-11 Borgwarner Inc. Method for controlling a dual clutch transmission
JP2007518827A (ja) * 2004-02-02 2007-07-12 シェーリング コーポレイション Cd200およびcd200rを調節する方法

Similar Documents

Publication Publication Date Title
CN102639564B (zh) 抗-cmet抗体及其用于癌症的检测和诊断的用途
JP2019116474A5 (cg-RX-API-DMAC7.html)
JP4280803B2 (ja) 慢性リンパ性白血病細胞株および抗体を産生するためのその使用
JP2009517057A5 (cg-RX-API-DMAC7.html)
CN103827144B (zh) 新的抗cxcr4抗体及其用于检测和诊断癌症的用途
JP2020522513A5 (cg-RX-API-DMAC7.html)
JP7245358B2 (ja) 抗cd25抗体及びその適用
JP2021520208A5 (cg-RX-API-DMAC7.html)
JP2013506428A5 (cg-RX-API-DMAC7.html)
JP2012176953A5 (cg-RX-API-DMAC7.html)
KR20130100963A (ko) 암의 진단 및/또는 예후를 위한 새로운 항체
WO2006020266A2 (en) Polypeptides and antibodies derived from chronic lymphocytic leukemia cells and uses thereof
JP2021517152A5 (cg-RX-API-DMAC7.html)
JP2009509538A5 (cg-RX-API-DMAC7.html)
WO2013017562A1 (en) Use of the antibody i-3859 for the detection and diagnosis of cancer
JP2023157927A (ja) 多発性骨髄腫におけるmタンパク質反応の臨床評価
WO2017114973A1 (en) Compositions and methods for assessing the risk of cancer occurrence
US12091457B2 (en) Use for preventing and treating myeloid-derived suppressor cell-related diseases
JP2020515286A5 (cg-RX-API-DMAC7.html)
US20240117042A1 (en) Immunohistochemistry methods and kir3dl2-specific reagents
WO2016174053A1 (en) Igf-1r antibody and its use for the diagnosis of cancer
US20230192900A1 (en) Bispecific antibodies binding hvem and cd9
JP2023516705A5 (cg-RX-API-DMAC7.html)
JP2021516989A5 (cg-RX-API-DMAC7.html)
JP7821779B2 (ja) 抗体を使用した細胞表面mica及びmicbの検出